Join
Live feed
·
PRReleasevia Quantisnow
Cognition Therapeutics Inc. logo

Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies

ByQuantisnow·Wall Street's wire, on your screen.
CGTX· Cognition Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CGTX (Cognition Therapeutics Inc.) and more on Quantisnow.